The Impact of New Data Released at ASH 2022 on the Treatment Landscape of CML and Ph+ ALL

home / insights / the-impact-of-new-data-released-at-ash-2022-on-the-treatment-landscape-of-cml-and-ph-all

Neal Dave, PharmD, and Brandon Dyson, PharmD, BCOP, BCPS, share insights regarding the treatment landscape for patients with CML and Ph+ ALL.

EP. 1: Current Standards of Care in Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) and Philadelphia Chromosome-Positive ALL (Ph+ ALL)

December 22nd 2022

Medical experts open a discussion on treatment management for patients with CP-CML and Ph+ ALL.

Watch

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.